share_log

Piper Sandler Maintains Overweight on Akoya Biosciences, Lowers Price Target to $8

Benzinga ·  Nov 13, 2023 16:09

Piper Sandler analyst David Westenberg maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $11 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment